Gilead Sciences, Inc. (VIE:GILD)

Market Cap	118.95B
Revenue (ttm)	24.58B
Net Income (ttm)	5.37B
Shares Out	n/a
EPS (ttm)	4.27
PE Ratio	22.14
Forward PE	13.26
Dividend	2.82 (2.96%)
Ex-Dividend Date	Sep 15, 2025

Volume	107
Average Volume	30
Open	95.26
Previous Close	95.36
Day's Range	95.14 - 95.73
52-Week Range	73.64 - 111.52
Beta	n/a
RSI	42.28
Earnings Date	Nov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD